Manufacturers

Opportunities and pain points for CGT innovation and market access

Manufacturers

Planning for the World: Q&A With Sandra Anderson, SVP of International Commercialization at Cencora

Manufacturers

Addressing Barriers to Patient Care for People Living With Atopic Dermatitis

Shaping the future of healthcare: Our thought leadership at ISPOR Europe 2023

Manufacturers

Anticipating the top seven global market access trends for 2024: Cencora’s healthcare landscape outlook 

Manufacturers

Podcast: How 2023 will shape the US Biosimilar space for 2024 and beyond

Manufacturers

Podcast: The race to develop innovative products and supply chain solutions 

Manufacturers

The Dutch Lock Procedure for Reimbursement: Ensuring Effective and Affordable Healthcare

Manufacturers

Streamlining Patient Access to Cell and Gene Therapies

Manufacturers

Enhancing Patient-Reported Outcomes (PROs) in German AMNOG Assessments: Insights from the ISPOR Europe 2023 Conference

Manufacturers

Work worth doing: Innovative field solutions

Manufacturers

Will the IRA hinder the potential of Biosimilars?

Manufacturers

Exploring the Implications of Differing PICO Criteria for Oncology Drug Assessments in Europe

Manufacturers

Avoiding CGT commercialization pitfalls

Manufacturers

Webinar on demand: Implications of the EU JCA on patient access and engagement

Manufacturers

Essential skills for outsourced field solutions teams

Manufacturers

3 reasons biopharma uses shared resources for its field support team

Manufacturers

Does the EU HTAR really put patients at the center?

Manufacturers

The more things change, the more they stay the same? Reviewing ICER's revised value assessment framework

Manufacturers

Navigating the way to the new EU JCA—Are biopharma companies, HTA bodies, patients, and clinicians sufficiently prepared? 

Manufacturers

Checklist: Why you need a learning solutions partner with market access and reimbursement expertise

Manufacturers

Cell and gene therapy trials — The synergy of CRO and specialty logistics collaboration

Manufacturers

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

Manufacturers

Advancing Cell and Gene Therapy (CGT) Access: Insights from CAR-TCR 2023

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

HTA Quarterly | Fall 2023

Manufacturers

Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties

Manufacturers

Multistakeholder perspectives on Joint Clinical Assessment in Europe

Manufacturers

What's next for biopharma under the inflation reduction act

Manufacturers

Pre-launch checklist: What to look for in a commercialization partner

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

Optimize your pre-approval information exchange strategy

Manufacturers

How to forge stronger working relationships with payers

Manufacturers

HTA Quarterly | Spring 2023

Manufacturers

The essential guide to drug commercialization

Manufacturers

Six essential steps for emerging biopharma companies launching a new therapy

Manufacturers

Three questions biopharma companies must ask when building a cell and gene commercialization strategy

Manufacturers

Education: The centerpiece of biosimilar adoption

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

Manufacturers

Webinar: Evaluate alternative revolutionary reimbursement models to craft a sustainable business model for cell and gene therapies

Manufacturers

Three questions to ask about your market access partner

Manufacturers

Acceleration of innovation in healthcare delivery

Manufacturers

HTA Quarterly | Summer 2023

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

Podcast: Conversations around interchangeability and biosimilar entries in new therapeutic categories

Manufacturers

Closing the gaps in pre-approval information exchange to accelerate product success and patient access

Manufacturers

Answering the challenges of rare disease market access with HEOR

Manufacturers

How will the Inflation Reduction Act affect the biopharma industry?

Manufacturers

Market access abroad: Three reasons why early planning is critical for HTA countries

Manufacturers

Podcast: Milestones for biosimilars in 2022 and looking ahead to 2023

Manufacturers

Innovative agreements: Exploring alternative payment models

Manufacturers

Why FormularyDecisions® is the right choice for enterprise biopharma payer engagement 

Manufacturers

Webinar slides: Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies

Orphan drugs: trapped in the lock? A review of the lock system in the Netherlands

Manufacturers

Differentiate your product with FormularyDecisions®

Manufacturers

Six insights driving the evolution of FormularyDecisions®

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

Manufacturers

Building your field reimbursement and access team: The translational experience and skills that matter most

Manufacturers

eBook: Bringing innovation to market with digital therapeutics

Manufacturers

Navigating the payer landscape for digital therapeutics

Manufacturers

Patient support for digital therapeutics: Do's and don'ts for designing your program

Manufacturers

Innomar Strategies: 20 years of innovative market access solutions

Manufacturers

Work worth doing: FormularyDecisions

Manufacturers

Podcast: ThinkLive Commercialization 2021

Manufacturers

On-demand webinar: Accelerating access to therapy (a view from the front lines)

Manufacturers

The hidden value of integrated commercialization services: A manufacturer’s perspective

Manufacturers

The Value of Real-World Evidence in Canadian Drug Commercialization: Part 2

Manufacturers

How to make the most of integrated commercialization solutions

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

Manufacturers

Webinar: uptake or heartbreak with biosimilars? Progress and perspectives

Manufacturers

Checklist: Four things to look for in a field services partner

Manufacturers

Case study: an innovative field reimbursement program expands patient access

Manufacturers

Cell and gene therapies: bringing innovation to market

Manufacturers

Pharma in the field: Ashley's story

Manufacturers

Pharma in the field: Tierra's story

Manufacturers

Ebook: Virtual drug commercialization

Manufacturers

Is a contact-free clinical trial possible?

Patient support launch guide: novel therapies 

Manufacturers

Is your PIE incomplete?

Case study: Gaining payer attention through digital innovation

Manufacturers

Rethink field services: Three myths keeping access barriers in front of your product

Manufacturers

Solving access, reimbursement, and PAP awareness problems

Manufacturers

Pharma in the field: Sales reps vs. reimbursement and access specialists

Manufacturers

The Future of Payer Engagement: How Pharma Can Break Through

Manufacturers

The Value of Virtual: How Remote Workshops Can Keep Market Access Efforts Moving

Manufacturers

Distant But Engaged: Transitioning to Virtual Training

Manufacturers

Mind the (Evidence) Gap

Manufacturers

InnomarLive 2019: Commercializing in Canada

Manufacturers

Biosimilars: Market Insights and Growth Factors

Manufacturers

Biosimilars: Launch Insights From the Field

Manufacturers

How Digital Innovation Drives Improved Market Access Strategies

Health Systems

Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Infographic: The Road to Commercialization in Canada

Manufacturers

What Do Payers Think About Digital Health Technologies

Manufacturers

The Route to Market Access in Canada